Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

HER2 expression remains an important biomarker to guide the addition of the monoclonal antibody trastuzumab to first-line systemic chemotherapy in unresectable, metastatic gastroesophageal adenocarcinomas (GEA). However, in contrast to breast cancer, other HER2-targeted strategies to date have not i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Dan, Klempner, Samuel J., Chao, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525398/
https://www.ncbi.nlm.nih.gov/pubmed/31101074
http://dx.doi.org/10.1186/s13045-019-0737-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525398/
https://www.ncbi.nlm.nih.gov/pubmed/31101074
http://dx.doi.org/10.1186/s13045-019-0737-2

Ejemplares similares